CD8A and cancer: Subsequently, Tregs inhibit the differentiation and proliferation of cancer killing (cytotoxic) effector CD8+ T cells through inhibition of IL-2 production [43] and inhibit the maturation and antigen presenting function of dendritic cells (DCs) [44].